Efficacy of Plasmapheresis and Immunoglobulin Replacement Therapy (IVIG) on Patients with COVID-19

doi:10.1007/s42399-020-00438-2

Review

. 2020;2(9):1407-1411.

doi: 10.1007/s42399-020-00438-2. Epub 2020 Jul 31.

Efficacy of Plasmapheresis and Immunoglobulin Replacement Therapy (IVIG) on Patients with COVID-19

Ramtin Pourahmad¹, Bobak Moazzami^{1

2}, Nima Rezaei^{1

2}

Affiliations

¹ Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran.
² Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.

PMID: 32838178
PMCID: PMC7392618
DOI: 10.1007/s42399-020-00438-2

Review

Efficacy of Plasmapheresis and Immunoglobulin Replacement Therapy (IVIG) on Patients with COVID-19

Ramtin Pourahmad et al. SN Compr Clin Med. 2020.

. 2020;2(9):1407-1411.

doi: 10.1007/s42399-020-00438-2. Epub 2020 Jul 31.

Authors

Ramtin Pourahmad¹, Bobak Moazzami^{1

2}, Nima Rezaei^{1

2}

Affiliations

¹ Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran.
² Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.

PMID: 32838178
PMCID: PMC7392618
DOI: 10.1007/s42399-020-00438-2

Abstract

Since the rapidly evolving outbreak of COVID-19, several empirical therapeutic options have been recommended including the use of antivirals, steroids, and vaccines. According to recent observations about different modalities in treatment of patients infected with COVID-19, plasmapheresis and intravenous immunoglobulin (IVIg) have been reported to be an effective empirical therapeutic option to control the infection. In this review, we aimed to provide an overview on the possible application of plasmapheresis and intravenous immunoglobulin in patients with COVID-19.

Keywords: COVID-19; Coronavirus; Intravenous immunoglobulin; Plasmapheresis; Treatment.

PubMed Disclaimer

Conflict of interest statement

Conflict of InterestThe authors declare that they have no conflict of interest.

Cited by

_targeting Macrophage Dysregulation for Viral Infections: Novel _targets for Immunomodulators.
Reece MD, Taylor RR, Song C, Gavegnano C. Reece MD, et al. Front Immunol. 2021 Nov 1;12:768695. doi: 10.3389/fimmu.2021.768695. eCollection 2021. Front Immunol. 2021. PMID: 34790202 Free PMC article. Review.
A Review on Current Repurposing Drugs for the Treatment of COVID-19: Reality and Challenges.
Hossen MS, Barek MA, Jahan N, Safiqul Islam M. Hossen MS, et al. SN Compr Clin Med. 2020;2(10):1777-1789. doi: 10.1007/s42399-020-00485-9. Epub 2020 Aug 31. SN Compr Clin Med. 2020. PMID: 32904710 Free PMC article. Review.
A systematic review of pregnant women with COVID-19 and their neonates.
Mirbeyk M, Saghazadeh A, Rezaei N. Mirbeyk M, et al. Arch Gynecol Obstet. 2021 Jul;304(1):5-38. doi: 10.1007/s00404-021-06049-z. Epub 2021 Apr 2. Arch Gynecol Obstet. 2021. PMID: 33797605 Free PMC article. Review.
Therapeutic Plasma Exchanges in Combination with High-Dose Steroid-Induced Immunosuppression as an Ultima Ratio Therapy in Severe Coronavirus Disease 2019 (COVID-19): A Case-Series Report.
Janikowska A, Soukup J, Pliquett RU, Abdel-Rahim R. Janikowska A, et al. J Inflamm Res. 2022 Feb 3;15:715-722. doi: 10.2147/JIR.S344028. eCollection 2022. J Inflamm Res. 2022. PMID: 35140501 Free PMC article.
Computed tomography scan in COVID-19: a systematic review and meta-analysis.
Sharif PM, Nematizadeh M, Saghazadeh M, Saghazadeh A, Rezaei N. Sharif PM, et al. Pol J Radiol. 2022 Jan 5;87:e1-e23. doi: 10.5114/pjr.2022.112613. eCollection 2022. Pol J Radiol. 2022. PMID: 35140824 Free PMC article. Review.

See all "Cited by" articles

References

1. Cheng Y, Wong R, Soo YO, Wong WS, Lee CK, Ng MH, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2005;24(1):44–46. - PMC - PubMed
1. Koch B, Schult-Dietrich P, Büttner S, Dilmaghani B, Lohmann D, Baer PC, Dietrich U, Geiger H. Lectin affinity plasmapheresis for Middle East respiratory syndrome-coronavirus and Marburg virus glycoprotein elimination. Blood Purif. 2018;46(2):126–133. - PMC - PubMed
1. Zhao Y, Wang C, Qiu B, Li C, Wang H, Jin H, Gai W, Zheng X, Wang T, Sun W, Yan F, Gao Y, Wang Q, Yan J, Chen L, Perlman S, Zhong N, Zhao J, Yang S, Xia X. Passive immunotherapy for Middle East respiratory syndrome coronavirus infection with equine immunoglobulin or immunoglobulin fragments in a mouse model. Antivir Res. 2017;137:125–130. - PMC - PubMed
1. Keith P, Day M, Choe C, Perkins L, Moyer L, Hays E, et al. The successful use of therapeutic plasma exchange for severe COVID-19 acute respiratory distress syndrome with multiple organ failure. SAGE open medical case reports. 2020;8:2050313x20933473. - PMC - PubMed
1. Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, Wang F, Li D, Yang M, Xing L, Wei J, Xiao H, Yang Y, Qu J, Qing L, Chen L, Xu Z, Peng L, Li Y, Zheng H, Chen F, Huang K, Jiang Y, Liu D, Zhang Z, Liu Y, Liu L. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. Jama. 2020;323(16):1582–1589. - PMC - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Europe PubMed Central
- PubMed Central

[1] Cheng Y, Wong R, Soo YO, Wong WS, Lee CK, Ng MH, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2005;24(1):44–46. - PMC - PubMed

[2] Cheng Y, Wong R, Soo YO, Wong WS, Lee CK, Ng MH, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2005;24(1):44–46. - PMC - PubMed

[3] Koch B, Schult-Dietrich P, Büttner S, Dilmaghani B, Lohmann D, Baer PC, Dietrich U, Geiger H. Lectin affinity plasmapheresis for Middle East respiratory syndrome-coronavirus and Marburg virus glycoprotein elimination. Blood Purif. 2018;46(2):126–133. - PMC - PubMed

[4] Koch B, Schult-Dietrich P, Büttner S, Dilmaghani B, Lohmann D, Baer PC, Dietrich U, Geiger H. Lectin affinity plasmapheresis for Middle East respiratory syndrome-coronavirus and Marburg virus glycoprotein elimination. Blood Purif. 2018;46(2):126–133. - PMC - PubMed

[5] Zhao Y, Wang C, Qiu B, Li C, Wang H, Jin H, Gai W, Zheng X, Wang T, Sun W, Yan F, Gao Y, Wang Q, Yan J, Chen L, Perlman S, Zhong N, Zhao J, Yang S, Xia X. Passive immunotherapy for Middle East respiratory syndrome coronavirus infection with equine immunoglobulin or immunoglobulin fragments in a mouse model. Antivir Res. 2017;137:125–130. - PMC - PubMed

[6] Zhao Y, Wang C, Qiu B, Li C, Wang H, Jin H, Gai W, Zheng X, Wang T, Sun W, Yan F, Gao Y, Wang Q, Yan J, Chen L, Perlman S, Zhong N, Zhao J, Yang S, Xia X. Passive immunotherapy for Middle East respiratory syndrome coronavirus infection with equine immunoglobulin or immunoglobulin fragments in a mouse model. Antivir Res. 2017;137:125–130. - PMC - PubMed

[7] Keith P, Day M, Choe C, Perkins L, Moyer L, Hays E, et al. The successful use of therapeutic plasma exchange for severe COVID-19 acute respiratory distress syndrome with multiple organ failure. SAGE open medical case reports. 2020;8:2050313x20933473. - PMC - PubMed

[8] Keith P, Day M, Choe C, Perkins L, Moyer L, Hays E, et al. The successful use of therapeutic plasma exchange for severe COVID-19 acute respiratory distress syndrome with multiple organ failure. SAGE open medical case reports. 2020;8:2050313x20933473. - PMC - PubMed

[9] Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, Wang F, Li D, Yang M, Xing L, Wei J, Xiao H, Yang Y, Qu J, Qing L, Chen L, Xu Z, Peng L, Li Y, Zheng H, Chen F, Huang K, Jiang Y, Liu D, Zhang Z, Liu Y, Liu L. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. Jama. 2020;323(16):1582–1589. - PMC - PubMed

[10] Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, Wang F, Li D, Yang M, Xing L, Wei J, Xiao H, Yang Y, Qu J, Qing L, Chen L, Xu Z, Peng L, Li Y, Zheng H, Chen F, Huang K, Jiang Y, Liu D, Zhang Z, Liu Y, Liu L. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. Jama. 2020;323(16):1582–1589. - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Efficacy of Plasmapheresis and Immunoglobulin Replacement Therapy (IVIG) on Patients with COVID-19

Affiliations

Efficacy of Plasmapheresis and Immunoglobulin Replacement Therapy (IVIG) on Patients with COVID-19

Authors

Affiliations

Abstract

Conflict of interest statement

Similar articles

Cited by

References

Publication types

LinkOut - more resources

Full Text Sources